natgillin/translations-raw huggingface dataset:
Despite any limitations of historical comparisons with other locally applied medicinal products, it can be concluded that exposure to estradiol after administration of Linoladiol N is considerably higher than after administration of other lower dosed estradiol products for topical intravaginal therapy. 
Kljub omejitvam zgodovinskih primerjav z drugimi lokalnimi zdravili je mogoče sklepati, da je izpostavljenost estradiolu po uporabil zdravila Linoladiol N znatno večja kot po uporabi drugih zdravil z majhnim odmerkom estradiola za topično intravaginalno zdravljenje.
0.01 % w/w estradiol containing medicinal products for topical use (Linoladiol N) The CHMP took into account all available data on pharmacokinetics (PK), dose-finding, efficacy and safety, including endometrial safety, of products for intravaginal administration and/or administration on the skin of the vulva containing estradiol, and also the well-known risks of systemic hormonal replacement therapy (HRT) in the approved therapeutic indication. 
Odbor CHMP je upošteval vse razpoložljive podatke o farmakokinetiki (FK), določanju odmerka, učinkovitosti in varnosti, vključno z varnostjo za endometrij, za zdravila za intravaginalno uporabo in/ali uporabo na koži vulve, ki vsebujejo estradiol, ter o dobro znanih tveganjih sistemskega hormonskega nadomestnega zdravljenja (HNZ) pri odobreni terapevtski indikaciji.
Two group of products represented by Linoladiol N (cream, 0.01% w/w estradiol), and Linoladiol HN (cream, 0.005% w/w estradiol and 0.4%w/w prednisolone) were assessed in this procedure. 
V tem postopku so ocenili dve skupini zdravil, ki sta jih predstavljali zdravili Linoladiol N (krema, 0,01 % m/m estradiola) in Linoladiol HN (krema, 0,005 % m/m estradiola ter 0,4 % m/m prednizolona).
Vaginal oestrogen therapy has been shown to provide improvement in the signs and symptoms of vaginal atrophy. 
Pokazali so, da nožnično estrogensko zdravljenje izboljša znake in simptome nožnične atrofije.
The MAH agreed to limit the maximum duration of treatment to four weeks and to restrict the route of administration to intravaginal administration only which addresses the concerns regarding long term exposure data and missing study data in question of treatment of skin of the vulva. 
Imetnik dovoljenja za promet z zdravilom se je strinjal z omejitvijo trajanja zdravljenja na štiri tedne in omejitvijo načina uporabe samo na intravaginalno uporabo, kar je naslovilo pomisleke glede podatkov o dolgotrajni izpostavljenosti in manjkajočih podatkov iz študij, povezanih z zdravljenjem kože zunanjih spolovil.
Clinical guidelines2,3 propose the use of topical oestrogens after lack of/inadequate response to nonhormonal vaginal lubricants / moisturisers, and other non-hormonal interventions. 
Klinične smernice23 predlagajo uporabo topičnih estrogenov, kadar je odziv na nehormonske nožnične lubrikante/vlažilna sredstva in druge nehormonske intervencije odsoten/nezadosten.
In comparison, after a single dose of Linoladiol N, Cmax without baseline correction was 393 pmol/l, Caverage without baseline correction during the first 24 h was 178 pmol/l (Lauritzen, 1992; Göres, 1995 and Mazur, 2003). 
V primerjavi s tem je bila vrednost Cmax ob enkratnem odmerku zdravila Linoladiol N (brez prilagajanja glede na izhodišče) 393 pmol/l, Cpovprečje (brez prilagajanja glede na izhodišče) v prvih 24 urah pa 178 pmol/l (Lauritzen 1992, Göres 1995 in Mazur 2003).
The available pharmacokinetic data demonstrate that estradiol is systemically absorbed after intravaginal application of Linoladiol N. PK data from study SCO 5174 indicate that estradiol concentrations after 6h of administration (Cmax 92.2 pg/ml) peak well above recommended postmenopausal levels and had not returned back to baseline levels after 36h of administration (likely reflecting trough levels). 
Razpoložljivi farmakokinetični podatki kažejo, da se estradiol sistemsko absorbira po intravaginalni uporabi zdravila Linoladiol N. Farmakokinetični podatki iz študije SCO 5174 prav tako kažejo, da so koncentracije estradiola 6 ur po uporabi (Cmax 92,2 pg/ml) precej večje od priporočenih postmenopavzalnih ravni in se v 36 urah po uporabi niso vrnile na izhodiščno raven.
Taking into account baseline corrected values, Cmax and Caverage in the 24 h interval after drug administration were 175 pmol/l and 55 pmol/l, respectively, regarding estradiol vaginal tablets 25 mcg, and 331 pmol/l and 120 pmol/l, respectively, regarding Linoladiol N. 
Upoštevajoč glede na izhodišče prilagojene vrednosti sta bili vrednosti Cmax in Cpovprečje v 24 urah po uporabi zdravila 175 pmol/l oziroma 55 pmol/l pri vaginalnih tabletah s 25 µg estradiola in 331 pmol/l oziroma 120 pmol/l pri zdravilu Linoladiol N.
As vaginal atrophy due to oestrogen deficiency in post-menopausal women is a chronic condition, recurrence of signs and symptoms is expected when topical oestrogen therapy is withdrawn. 
Ker je atrofija nožnice zaradi pomanjkanja estrogena pri postmenopavzalnih ženskah kronično stanje, je ponoven pojav znakov in simptomov po prekinitvi zdravljenja z estrogeni pričakovan.
Primarily the MAH disagreed with the recommended restriction of indication for Linoladiol N of “Treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women when at least one lower dose topical oestrogen treatment has failed”. 
Primarno se imetnik dovoljenja za promet z zdravilom ni strinjal s priporočeno omejitvijo indikacije za zdravilo Linoladiol N „Zdravljenje atrofije nožnice zaradi pomanjkanja estrogena pri postmenopavzalnih ženskah, kadar je bilo topično zdravljenje z vsaj enim estrogenom v manjšem odmerku neuspešno“.
No studies were submitted on the cutaneous use of Linoladiol N in the external genital area. 
Študije o kožni uporabi zdravila Linoladiol N na zunanjih spolovilih niso bile predložene.
• The Committee is of the opinion that the benefit does not outweigh the risk in the indication of lichen sclerosus genitalis for the 0.005 % w/w estradiol with 0.4 % w/w prednisolone containing medicinal products, in line with current clinical knowledge and therefore this indication should be deleted. 
• odbor je menil, da pri indikaciji za lichen sclerosus genitalis korist zdravil, ki vsebujejo 0,005 % m/m estradiola in 0,4 % m/m prednizolona, ni večja od tveganja, kar je skladno s trenutnim kliničnim znanjem, zato je treba to indikacijo izbrisati;
During the referral procedure a comparison of Linoladiol N available PK data with other locally applied medicinal products was made. 
Med napotitvenim postopkom se je opravila primerjava farmakokinetičnih podatkov, razpoložljivih za zdravilo Linoladiol N, in drugih lokalnih zdravil.
Based on the higher dose and substantial systemic estradiol exposure this product is more comparable to systemic HRT products from a safety point of view. 
Zaradi velikega odmerka in pomembne sistemske izpostavljenosti estradiolu je to zdravilo z vidika varnosti bolj primerljivo z zdravili za sistemsko hormonsko nadomestno zdravljenje.
• For the 0.01% w/w estradiol containing medicinal products for topical use the Committee considered that in view of the currently available data, the benefit-risk balance is favourable in the currently authorised indication, subject to restrictions, warnings and other changes to the product information, as well as further risk minimisation measures agreed. 
• odbor je za zdravila, ki vsebujejo 0,01 % m/m estradiola, menil, da je na podlagi trenutno razpoložljivih podatkov razmerje med tveganji in koristmi za trenutno odobreno indikacijo pozitivno, če se upoštevajo dogovorjene omejitve, opozorila in druge spremembe informacij o zdravilu ter nadaljnji dogovorjeni ukrepi za zmanjševanje tveganja.
The MAH favoured the initial indication of “Treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women”. 
Imetnik dovoljenja za promet z zdravilom je zagovarjal prvotno indikacijo „Zdravljenje atrofije nožnice zaradi pomanjkanja estrogena pri postmenopavzalnih ženskah“.
In this study, mean estradiol serum concentrations at baseline and at day 31 (i.e. about 36 h after administration of study medication on day 29) were 6.4 pg/ml and 15.1 pg/ml, respectively, in the Linoladiol N group and 4.4 pg/ml and 6.2 pg/ml, respectively, in the placebo group. 
V tej študiji so bile povprečne koncentracije estradiola v serumu v skupini z zdravilom Linoladiol N 6,4 pg/ml ob izhodišču in 15,1 pg/ml na 31. dan (tj. 36 ur po uporabi preiskovanega zdravila na 29. dan), v skupini s placebom pa 4,4 pg/ml oziroma 6,2 pg/ml.
Secondary test parameters included symptoms of vaginal atrophy and vaginal pH. With regard to the VMI, Linoladiol N was statistically significantly superior to placebo (mean VMI Linoladiol N group: at baseline 24.47%, on day 31, 64.23%; placebo group: baseline 32.01%, day 31 37.17%). 
Pri maturacijskem indeksu je bilo zdravilo Linoladiol N statistično pomembno boljše v primerjavi s placebom (povprečni MI v skupini z zdravilom Linoladiol N: ob izhodišču 24,47 %, 31. dan 64,23 %; v skupini s placebom: izhodišče 32,01 %, 31. dan 37,17 %).
The CHMP agreed with the MAH that not only dose, but also absorption and systemic concentrations of topically administered estradiol are of interest. 
Odbor CHMP se je strinjal z imetnikom dovoljenja za promet z zdravilom, da je treba poleg odmerka obravnavati tudi absorpcijo in sistemske koncentracije topičnega estradiola.
The authors state that in postmenopausal women reporting vaginal symptoms as their only complaint, these symptoms can be safely and effectively managed with low-dose oestrogen therapy, which reduces the risks associated with long-term systemic hormone therapy. 
težavi, ti simptomi varno in učinkovito obvladujejo z zdravljenjem z majhnimi odmerki estrogena, kar zmanjša tveganje, povezano z dolgotrajnim sistemskim hormonskim zdravljenjem.
Based on the totality of the data available on the safety and the efficacy of 0.01% w/w estradiol containing medicinal products to-date the CHMP confirmed that the benefit-risk balance remains favourable subject to the restrictions, warnings, changes to the product information, and risk minimisation measures agreed. 
Na podlagi vseh razpoložljivih podatkov o varnosti in učinkovitosti zdravil, ki vsebujejo 0,01 % m/m estradiola, je odbor CHMP potrdil, da razmerje med koristmi in tveganji ostaja pozitivno, če se upoštevajo dogovorjene omejitve, opozorila, spremembe informacij o zdravilu in ukrepi za zmanjševanje tveganja.
The Committee concluded that the benefit-risk balance of 0.005 % w/w estradiol, 0.4 % w/w prednisolone containing medicinal products for topical use for the initial short-term external treatment of acute, mild, inflamed, burning and itching skin diseases of the external female genital area in postmenopausal patients, for which weak-acting corticosteroids and low-dose estradiol are indicated remains positive subject to the restrictions, warnings, changes to the product information agreed. 
Odbor je sklenil, da razmerje med tveganji in koristmi za zdravila, ki vsebujejo 0,005 % m/m estradiola in 0,4 % m/m prednizolona, pri začetnem topičnem, kratkotrajnem zunanjem zdravljenju akutnih, blagih, vnetnih, pekočih ter srbečih kožnih bolezni ženskih zunanjih spolovil pri postmenopavzalnih ženskah, pri katerih so indicirani šibki kortikosteroidi in majhni odmerki estradiola, ostaja pozitivno, če se upoštevajo dogovorjene omejitve, opozorila in spremembe informacij o zdravilu.
0.005 % w/w estradiol/0.4 % w/w prednisolone containing medicinal products for topical use (Linoladiol HN) 
Zdravila za topično uporabo, ki vsebujejo 0,005 % m/m estradiola/0,4 % m/m prednizolona (Linoladiol HN)
The Committee concluded that the benefit-risk balance of 0.01% w/w estradiol containing medicinal products for the short-term external treatment of vaginal atrophy in postmenopausal patients when at least one topical oestrogen treatment has failed remains positive subject to the restrictions, warnings, changes to the product information agreed. 
Odbor je sklenil, da razmerje med tveganji in koristmi za zdravila, ki vsebujejo 0,01 % m/m estradiola, pri kratkotrajnem zunanjem zdravljenju vaginalne atrofije pri postmenopavzalnih ženskah, kadar je bilo neuspešno vsaj eno topično zdravljenje z estrogeni, ostaja pozitivno, če se upoštevajo dogovorjene omejitve, opozorila in spremembe informacij o zdravilu.
There were two main scientific points of disagreement with the CHMP opinion addressed in the MAH's grounds for re-examination. 
V razlogih za ponoven pregled je imetnik dovoljenja za promet z zdravilom izpostavil dve glavni strokovni točki, pri katerih se ne strinja z mnenjem odbora CHMP.
The Committee, as a consequence, concluded that the benefit-risk balance of the 0.01% w/w estradiol containing medicinal products for topical use as well as the 0.005 % w/w estradiol and 0.4 % w/w prednisolone containing medicinal products for topical use remains favourable subject to variation to the term of the marketing authorisation consisting of restrictions, warnings, and other changes to the product information, as well as the risk minimisation measures agreed, as applicable. 
posledično je odbor sklenil, da razmerje med tveganji in koristmi zdravil za topično uporabo, ki vsebujejo 0,01 % m/m estradiola, in zdravil za topično uporabo, ki vsebujejo 0,005 % m/m estradiola ter 0,4 % m/m prednizolona, ostaja pozitivno, če se upoštevajo spremembe pogojev dovoljenja za promet z zdravilom, ki vključujejo omejitve, opozorila in druge spremembe informacij o zdravilu, ter dogovorjeni ukrepi za zmanjševanje tveganja, kot je primerno.
Thus, a second line indication as proposed in the initial CHMP opinion i.e. the use of Linoladiol N after low-dose topical estradiol treatment has failed, although intended, is not explicitly stated in the international guidelines. 
Torej mednarodne smernice izrecno ne navajajo indikacije za zdravljenje druge izbire (čeprav nakazujejo nanjo), kot jo je odbor CHMP predlagal v svojem prvotnem mnenju, tj. uporaba zdravila Linoladiol N, kadar je bilo zdravljenje s topičnim estradiolom v majhnih odmerkih neuspešno.
Despite any limitations due to the historical comparisons, it can be concluded that the systemic exposure to estradiol observed for 
Kljub kakršnim koli omejitvam zaradi zgodovinskih primerjav je mogoče zaključiti, da je sistemska izpostavljenost estradiolu, ki so jo opazili pri zdravilu Linoladiol N, večja kot pri drugih zdravilih z estradiolom, namenjenih topični vaginalni uporabi.
information on supervision and appropriate warnings on e.g. endometrial hyperplasia and carcinoma, breast and ovarian cancer, need to be reflected in the appropriate section of the product information. 
Odbor CHMP je zato menil, da je treba zaradi morebitnih tveganj, povezanih z vsemi hormonskimi nadomestnimi zdravljenji, v ustrezno poglavje informacij o zdravilu vključiti informacije o nadzoru in ustrezna opozorila, npr. glede hiperplazije ter karcinoma endometrija, raka dojke in jajčnika.
If it occurs, the eyes should be rinsed slowly and gently with water. 
Če se to zgodi, je treba oči počasi in nežno spirati z vodo.
The expiry date refers to the last day of that month. 
Rok uporabnosti se nanaša na zadnji dan navedenega meseca.
A proper treatment of the pet´s environment by additional chemical or physical measures is recommended. 
Priporoča se primerna obdelava okolja ljubljenčka z dodatnimi kemičnimi ali fizikalnimi ukrepi.
Used pipettes should be disposed of immediately. 
Uporabljene merilne kapalke je treba takoj odstraniti.
This is not a sign of intoxication and disappears within some minutes without treatment. 
To ni znak zastrupitve in izgine v nekaj minutah samo od sebe.
Date of latest renewal: 07/01/2016. 
Datum zadnjega podaljšanja: 07/01/2016.
A dry white residue may be also observed. 
Včasih lahko opazite tudi suh bel ostanek.
These measures should help to protect the environment. 
Na ta način boste pomagali varovati okolje.
These effects will usually resolve without treatment. 
Ti učinki navadno izginejo brez zdravljenja.
• on the day of treatment, children must not handle treated animals and the animals should not be permitted to sleep with their owners, especially children; 
• na dan zdravljenja se otroci ne smejo dotikati zdravljenih živalmi in živali ne smejo spati z lastniki, posebno ne z otroki,
• avoid contact with eyes, as the product may cause moderate eye irritation. 
• izogibajte se stiku z očmi, ker zdravilo lahko povzroči zmerno draženje oči.
Activyl should not enter water courses as this may be dangerous for fish and other aquatic organisms. 
Activyl ne sme priti v vodne tokove, ker je lahko nevaren za ribe in druge vodne organizme.
ATCvet code: QP53AX27. 
Oznaka ATC vet: QP53AX27
The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD). 
Zdravilo za uporabo v veterinarski medicini se lahko uporablja kot del strategije zdravljenja dermatitisa zaradi alergije na bolhe (FAD).
A clear, colourless to yellow solution. 
Bistra brezbarvna do rumena raztopina.
In larger dogs, the entire contents of the pipette(s) should be applied evenly to 2-4 spots along the backline from the shoulder to the base of the tail. 
Pri večjih psih je treba vso vsebino merilne kapalke nanesti enakomerno na 2-4 mesta vzdolž hrbtenice od ramen do korena repa.
Consult a veterinarian if you intend to use the product on dogs with other products or medication. 
Posvetujte se z veterinarjem, če nameravate uporabiti zdravilo pri psih z drugimi zdravili ali medikacijo.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency, EMA) http://www.ema.europa.eu/).
Date of first authorisation: 18/02/2011. 
Datum pridobitve dovoljenja za promet: 18/02/2011.
The pipette consists of a blister film (polypropylene/cyclic-olefin-copolymer/polypropylene) and a foil lidstock (aluminium/polypropylene co-extruded) sealed into aluminium sachets. 
Merilna kapalka je sestavljena iz pretisnega filma (polipropilen/ciklični olefin kopolimer/polipropilen) in pokrovčka iz folije (stisnjen aluminij/polipropilen) in zavarjena v aluminijasto vrečko.
It enters the insect primarily through ingestion but is also absorbed, to a lesser degree, through the insect cuticle. 
V insekt pride predvsem z zaužitjem, se pa v manjši stopnji tudi absorbira skozi povrhnjico insekta.
All signs are generally reversible following supportive treatment. 
Vsi znaki navadno izginejo po podpornem zdravljenju.
The product remains effective following shampoo treatment, water immersion (swimming, bathing) and exposure to sunlight. 
Zdravilo še naprej učinkuje po šamponiranju, močenju (plavanje, kopanje) in izpostavljanju soncu.
Local and/or systemic reactions have been observed in some people after exposure. 
Pri nekaterih ljudeh so opazili lokalne in/ali sistemske reakcije po izpostavljenosti temu zdravilu.
Interaction with other medicinal products and other forms of interaction: Consult a veterinarian if you intend to use the product on cats with other products or medication. 
Medsebojno delovanje z drugimi zdravili in druge oblike medsebojnega delovanja Posvetujte se z veterinarjem, če nameravate uporabiti zdravilo pri mačkah z drugimi zdravili ali medikacijo.
Small cats 
Majhne mačke
6.6 - 10 Small dogs 
6,6-10 Majhni psi
Medicines should not be disposed of via wastewater or household waste. 
Ne odvrzite zdravil v odpadno vodo ali v gospodinjske odpadke.
People with known hypersensitivity to indoxacarb should avoid contact with this product. 
Ljudje z znano preobčutljivostjo na indoksakarb naj se izogibajo stiku s tem zdravilom.
Minimum of 25 
0,51 najmanj 25
Treatment and prevention of flea infestation (Ctenocephalides felis). 
Zdravljenje in preprečevanje infestacije z bolhami (Ctenocephalides felis).
Also contains isopropyl alcohol 354 mg/ml. 
Vsebuje tudi izopropilalkohol 354 mg/ml.
Following a single administration, the veterinary medicinal product will prevent further flea infestation for 4 weeks. 
Po enkratni uporabi zdravila za uporabo v veterinarski medicini bo to preprečevalo nadaljnjo infestacijo z bolhami za 4 tedne.
EU/02/10/118/003 EU/02/10/118/004 EU/02/10/118/005 EU/02/10/118/006 EU/02/10/118/007 EU/02/10/118/008 EU/02/10/118/009 EU/02/10/118/010 EU/02/10/118/015 EU/02/10/118/016 EU/02/10/118/017 EU/02/10/118/018 EU/02/10/118/019 
EU/02/10/118/001 EU/02/10/118/002 EU/02/10/118/003 EU/02/10/118/004 EU/02/10/118/005 EU/02/10/118/006 EU/02/10/118/007 EU/02/10/118/008 EU/02/10/118/009 EU/02/10/118/010 EU/02/10/118/015 EU/02/10/118/017 EU/02/10/118/018 EU/02/10/118/019
Step 1: The cat should be standing for easy application. 
Prvi korak: Mačka naj stoji, da je nanašanje lažje.
Step 1: The dog should be standing for easy application. 
Prvi korak: Pes naj stoji, da je nanašanje lažje.
The safety of the product has not been established in cats younger than 8 weeks of age. 
Varnost zdravila ni bila ugotovljena pri mačkah, mlajših od 8 tednov.
The safety of the product has not been established in cats weighing less than 0.6 kg. 
Varnost zdravila ni bila ugotovljena pri mačkah, ki tehtajo manj kot 0,6 kg.
The appropriate combination of pipettes should be used 
> 60 Uporabiti je treba primerno kombinacijo merilnih kapalk.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. 
Varnost zdravila za uporabo v veterinarski medicini v obdobju brejosti in laktacije ni bila ugotovljena.
To avoid adverse reactions: 
Da bi preprečili neželene učinke,
Apply the dose to an area where the dog cannot lick it off, as described in section 4.9. 
Odmerek nanesite na področje, kjer ga pes ne more polizati, kot je opisano v poglavju 4.9.
Manufacturer responsible for batch release: Intervet Productions S.A. 
Izdelovalec, odgovoren za sprostitev serije: Intervet Productions S.A.
In clinical studies, Activyl was co-administered with deltamethrin collars impregnated with up to 4% deltamethrin without evidence of associated adverse reactions. 
V kliničnih študijah so dajali Activyl skupaj z ovratnicani, ki so bile impregnirane z do 4% deltametrina in niso ugotovili s tem povezanih stranskih učinkov.
Indoxacarb is a pro-drug that requires bioactivation by the insect enzymes to exert its pharmacodynamic effects. 
Indoksakarb je pro-zdravilo, ki ga morajo bioaktivirati encimi insekta, da začne farmakodinamsko učinkovati.
• administer the product in a well-ventilated area; 
• nanašajte zdravilo v dobro zračenem prostoru,
Efficacy against new infestations with fleas persists for 4 weeks following a single application. 
Učinkovitost proti novim infestacijam se obdrži 4 tedne po enem dajanju.
VIRBAC DE PORTUGAL, LABORATÓRIOS LDA, R.do Centro Empresarial, Ed13-Piso 1- Esc.3, 
VIRBAC DE PORTUGAL, LABORATÓRIOS LDA, R.do Centro Empresarial, Ed13-Piso 1- Esc.3, Quinta da Beloura,
Cardboard box with 1, 4 or 6 sachets; each sachet contains one unit-dose pipette. 
Kartonska škatla z 1, 4 ali 6 vrečkami, v vsaki vrečki je ena merilna kapalka z enim odmerkom.
After being converted into a metabolite, indoxacarb is active against adult, larval and egg stages of insects. 
Ko se pretvori v metabolit, indoksakarb deluje na odrasle insekte, njihove ličinke in jajčeca.
Do not administer orally or via any other route. 
Ne dajajte ga peroralno ali kakorkoli drugače.
If symptoms occur, seek medical advice and show the package leaflet to your physician. 
Če se pojavijo simptomi, se posvetujte z zdravnikom in mu pokažite navodilo za uporabo.
Squeeze the pipette firmly and apply the entire contents directly to the skin. 
Merilno kapalko močno stisnite in vso vsebino nanesite neposredno na kožo.
For the full list of excipients, see section 6.1. 
354 mg/ml Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Following a single spot-on application of the product, indoxacarb can still be detected in both skin and hair coat after 4 weeks post-treatment. 
Po enkratnem nanosu raztopine indoksakarb še vedno lahko odkrijemo tako v koži kot v dlaki 4 tedne po nanosu.
One size of unit-dose pipette only per box. 
Samo ena velikost merilne kapalke z enim odmerkom v škatli.